screeningprotocol.This relative advantage has proven to be stable from year 7 to year 13 after the beginning of screening.Still,the disadvantages of overdiagnosis and overtreatment are the downsides of a population-based screening approach.But given the overall advantage of screening,a risk-adapted ...
Although the widespread use of prostate-specific antigen (PSA) testing has led to an increase in the number of cancers detected, controversies about the benefits of screening persist. No conclusive evidence has yet emerged that PSA screening reduces the mortality associated with prostate cancer. Thus...
Ectopic expression of the anti-apoptotic gene Bcl2 was not sufficient for cells with damaging mutations to reach the LZ, suggesting that BCR-dependent cues may actively facilitate the transition. Thus, BCR replacement and pre-screening in DZs prevents the accumulation of clones with non-functional ...
Latner, Ann W
Several questions and answers on non-screening Prostate-Specific Antigen (PSA) covered by medicare are presented including one on checking PSA in a patient on testosterone therapy, pre-authorization for ...
and difficulties with clinical screening and translation are the key barriers to synthetic lethality. Recent studies have shown that cancer cells with altered DNA repair mechanisms are ideal candidates for therapies based on synthetic lethality approaches. According to this viewpoint, pharmacological combina...